TY - JOUR
T1 - Body distribution of nanoparticle-containing adriamycin injected into the hepatic artery of hepatoma-bearing rats
AU - Chen, Jiang Hao
AU - Wang, Ling
AU - Ling, Rui
AU - Li, Yu
AU - Wang, Zhe
AU - Yao, Qing
AU - Ma, Zhong
PY - 2004/8
Y1 - 2004/8
N2 - The aim of the study was to investigate the body distribution of nanoparticle-containing adriamycin (NADR) injected into the hepatic artery of hepatoma-bearing rats. Thirty Walker-256 hepatoma-bearing rats were divided into two groups at random, with 15 rats in each. NADR and free adriamycin (FADR) were injected into the hepatic artery of animals on the seventh day after tumor implantation. At 1, 5, and 15 hr, after administration, five animals in each group were sacrificed and the ADR concentrations in the plasma, liver, heart, spleen, lungs, kidneys, and tumor were determined. The results showed that NADR substantially increased the ADR concentrations in liver, spleen, and tumor of rats compared to FADR, whereas the concentrations in plasma, heart, and lungs were significantly decreased. In conclusion, the body distribution of ADR can be modified by its encapsulation into nanoparticles and administration via the hepatic artery.
AB - The aim of the study was to investigate the body distribution of nanoparticle-containing adriamycin (NADR) injected into the hepatic artery of hepatoma-bearing rats. Thirty Walker-256 hepatoma-bearing rats were divided into two groups at random, with 15 rats in each. NADR and free adriamycin (FADR) were injected into the hepatic artery of animals on the seventh day after tumor implantation. At 1, 5, and 15 hr, after administration, five animals in each group were sacrificed and the ADR concentrations in the plasma, liver, heart, spleen, lungs, kidneys, and tumor were determined. The results showed that NADR substantially increased the ADR concentrations in liver, spleen, and tumor of rats compared to FADR, whereas the concentrations in plasma, heart, and lungs were significantly decreased. In conclusion, the body distribution of ADR can be modified by its encapsulation into nanoparticles and administration via the hepatic artery.
KW - cancer
KW - drug metabolism
KW - experimental
UR - http://www.scopus.com/inward/record.url?scp=4444313643&partnerID=8YFLogxK
U2 - 10.1023/B:DDAS.0000037807.96064.99
DO - 10.1023/B:DDAS.0000037807.96064.99
M3 - 文章
C2 - 15387341
AN - SCOPUS:4444313643
SN - 0163-2116
VL - 49
SP - 1170
EP - 1173
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 7-8
ER -
